1,5-(diethylamino)piperidine
Description
1,5-(Diethylamino)piperidine, also known as **DEP**, is a **heterocyclic amine** with a piperidine core structure and two ethyl groups attached to the nitrogen atom at position 1.
Here's why it's important in research:
* **Pharmacological Applications:**
* **Central Nervous System (CNS) Activity:** DEP has demonstrated various effects on the CNS, including **anticonvulsant**, **analgesic**, and **anxiolytic** properties. This has led to its investigation as a potential therapeutic agent for conditions like epilepsy, pain, and anxiety disorders.
* **Anticholinergic Activity:** DEP exhibits **anticholinergic effects**, meaning it blocks the actions of acetylcholine, a neurotransmitter important for muscle contraction and other bodily functions. This property has been explored in treating certain neurological disorders.
* **Modulation of Ion Channels:** Studies have suggested that DEP can interact with and modulate the activity of **ion channels**, particularly those involved in neuronal signaling. This could provide insights into its mechanism of action and potential therapeutic targets.
* **Chemical Synthesis and Drug Development:**
* **Versatile Building Block:** DEP is a valuable intermediate in **organic synthesis**. It serves as a building block for creating a wide range of structurally diverse compounds, including potential drugs with pharmacological activity.
* **Scaffold for Drug Discovery:** The piperidine ring system is commonly found in many pharmaceuticals. DEP's structure provides a starting point for developing new drug candidates by modifying the piperidine core with different functional groups.
* **Analytical Chemistry:**
* **Reference Standard:** DEP can act as a **reference standard** for analytical methods, allowing for accurate quantification and quality control of other compounds.
* **Analytical Reagent:** Its unique chemical properties make it useful as a **reagent** in various analytical procedures.
**In summary, 1,5-(Diethylamino)piperidine is important for research due to its pharmacological activity, its potential as a drug candidate, and its value in chemical synthesis and analytical chemistry.**
**However, it's crucial to note that DEP is not a clinically approved drug and research into its potential therapeutic applications is ongoing.** Further studies are necessary to understand its safety, efficacy, and optimal dosage for any potential medical use.
1,5-(diethylamino)piperidine: structure given in first source; a spermidine analogue that activates the N-methyl-D-aspartate receptor-associated polyamine site [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 4025 |
CHEMBL ID | 1365365 |
SCHEMBL ID | 2017128 |
MeSH ID | M0202944 |
Synonyms (15)
Synonym |
---|
LOPAC0_000834 |
NCGC00162268-01 |
NCGC00015635-03 |
143999-55-7 |
2-[6-(2-aminoethyl)piperidin-2-yl]ethanamine |
CCG-204918 |
NCGC00015635-02 |
1,5-deap |
1,5-(diethylamino)piperidine |
SCHEMBL2017128 |
CHEMBL1365365 |
2,2'-(piperidine-2,6-diyl)di(ethan-1-amine) |
DTXSID70932182 |
SDCCGSBI-0050811.P002 |
mdl-26,630 trihydrochloride |
Protein Targets (4)
Potency Measurements
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 0.2818 | 0.1000 | 20.8793 | 79.4328 | AID588453 |
USP1 protein, partial | Homo sapiens (human) | Potency | 26.6795 | 0.0316 | 37.5844 | 354.8130 | AID504865 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 8.9125 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 8.4921 | 0.0601 | 10.7453 | 37.9330 | AID485368 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Bioassays (19)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504836 | Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation | 2002 | The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16 | Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells. |
AID1347151 | Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
AID1347050 | Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
AID1347410 | qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library | 2019 | Cellular signalling, 08, Volume: 60 | A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening. |
AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID1347045 | Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
AID1347059 | CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
AID1347058 | CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID1347057 | CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
AID588378 | qHTS for Inhibitors of ATXN expression: Validation | |||
AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588349 | qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay | |||
AID1347049 | Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID1347405 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (12)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (8.33) | 18.2507 |
2000's | 1 (8.33) | 29.6817 |
2010's | 5 (41.67) | 24.3611 |
2020's | 5 (41.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.56
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 12 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |